Advanced Oncotherapy PLC (LON:AVO)

Advanced Oncotherapy PLC (LON:AVO)


Share Price
39.01 p
Change
-1.99 (-4.85 %)
Market Cap
£78.19 m
Proactive Investors - Run By Investors For Investors

Advanced Oncotherapy PLC

Advanced Oncotherapy is a specialist developer and provider of a breakthrough proton therapy system, the LIGHT system, which is the result of 25 years of work at CERN and ADAM.

Our focus is on developing and supplying technologies to maximise the destructive effect of radiation on tumours whilst minimising damage to the patient's healthy tissues.

Advanced Oncotherapy plc operates...

EPIC: AVO
Market: LSE:AVO
OTCBB:AONCF
FRA:R3I1
52-week High/Low: 57.00p / 33.00p
Sector: Health Care, Equipment & Services
Market Cap: £78.19 m
Website: www.avoplc.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Advanced Oncotherapy PLC


Advanced Oncotherapy PLC Snapshot

Our Values

At Advanced Oncotherapy, we are passionate about our Mission to defeat cancer and contribute to saving more lives with fewer side effects. We strive to show integrity, sincerity, reliability, commitment, consistency and competence throughout our work.

Our Leadership Team

Our leadership team brings decades of experience, knowledge, and expertise spanning all aspects of healthcare services. Meet the people leading our efforts to create a revolutionary approach to treat cancer.


Our Medical Advisers

The medical advisory board comprises distinguished scientists and leaders of medical research and physics institutions. It provides insight, scientific direction, and expertise to Advanced Oncotherapy’s leadership team.

Our Certification

We are dedicated to ensure that the infrastructure to develop and manufacture our product is safe, effective and reliable. Advanced Oncotherapy's and ADAM S.A.'s compliance with internationally recognised standards illustrates the importance that we place on the quality of our product. In January 2019, we obtained the ISO 13485:2016 certification having demonstrated the robustness of processes across our entire organisation, in accordance with the stringent requirements associated with a medical device.

Overview of the LIGHT System

Key Guiding Design Principles of our Proton Therapy System

The heart of the LIGHT system is its accelerator which has been designed as a series of modular units. Our ambition, as we develop the next generation of particle therapy systems, is threefold:

To overcome the costly infrastructure and extensive shielding requirements of first-generation cyclotrons

Thanks to its modular design, its lighter weight and its better proton efficiency, the LIGHT system has been designed to reduce the construction cost of the facility required to house it and makes proton therapy more accessible to local, smaller hospitals.

To offer increased precision

The linear design of LIGHT allows for (i) an active longitudinal modulation along the proton beam axis and (ii) the variation of the proton beam by electronic means during cancer treatment. The modular feature of LIGHT offers hospitals and treatment centres the flexibility to customise cancer treatment plans based on a wide range of energies. Potentially, this could provide an alternative to passive modulation, that degrades the beam along its path, causing it to lose integrity. Moreover, a dynamic transversal modulation allows a precise 3D treatment of the tumours via the 'spot scanning' technique.

Click here for more information.

 

The LIGHT Proton System Module by Module

A Compact, Integrated and Turn-key Solution for Proton Therapy

The LIGHT system uses innovative linear accelerators and hence does not require a cyclotron nor a synchrotron to accelerate the protons to the high energy levels needed. This means that neither the massive infrastructure, nor the extensive shielding associated with old and current forms of proton accelerators are required.

The LIGHT accelerator is integrated with a fully functional treatment room system that provides its functionality through a set of customizable services for the management and the implementation of a patient proton therapy treatment course. The integration of the various sub-systems is such that the clinical user will be working with one user interface related to the nozzle system, the patient positioning system, and the imaging system. Each of the software components is based on commercial, off-the-shelf components that are updated to support state-of-the-art and industry-standard communication protocols.

Click here for more information.

 

First LIGHT System: In Central London

Testimony of the Compact and Flexible Nature of LIGHT

Our priority is to install the LIGHT System close to where the patients live. Our first project in Harley Street, Marylebone, London, UK, is a clear demonstration of this. We have been working with the Howard de Walden Estate, the freehold owner of most of the buildings in Marylebone, as they aim at upholding the worldwide reputation of their medical properties concentrated around Harley Street. With its unique LIGHT technology, Advanced Oncotherapy can meet the objective of the Howard de Walden Estate. In 2015, Advanced Oncotherapy was granted a 50-year lease for a 15,000 sq ft facility and agreed to bear cost of redevelopment. The choice of the Howard de Walden Estate to equip a treatment centre in Harley Street with Advanced Oncotherapy's LIGHT proton therapy system further validates its modular design.

Click here for more information.

 

Partnership with STFC: A First Step to High Volume Production

A Strong Partnership with an Experienced Laboratory with Tremendous Track Record

While development of LIGHT is carried out at the Company’s CERN facilities in Geneva, Advanced Oncotherapy signed a major contract with the Science and Technology Facilities Council in 2018 to establish a UK assembly and testing centre for the LIGHT system. Locating its testing and assembly site at STFC's Daresbury Laboratory in the Liverpool City Region, within the UK’s research and innovation hub Sci-Tech Daresbury, with established infrastructure, a certified radiation site and a huge wealth of shared knowledge will enable AVO to quickly move forward with the construction of the first commercial LIGHT system in a cost-effective way.  STFC's Daresbury Laboratory offers the skills to project manage and deliver the bespoke accelerator infrastructure required by AVO. Susan Smith, Head of Daresbury Laboratory, commented: “It’s exciting to know that Daresbury Laboratory’s expertise in particle accelerators and facility construction will be contributing towards the success of this ground breaking physics and medical project.”

Click here for more information.

 

 

London, Switzerland, USA & Netherlands.

Dr Mike Sinclair
Executive Chairman | Appointed: Jun. 2006 | Nationality: British


Skills and experience


Held a number of appointments at teaching hospitals in London; registrar in Psychiatry at the Maudsley Hospital and Institute of Psychiatry of London University; more than 40 years of experience in the healthcare business.

Current Appointments


Executive Chairman.

Previous Appointments
Founder and Chief Executive of Nestor Healthcare and Allied Medical Group Limited; Chairman and Founder of Lifetime Corporation Inc; Member of the Board of Overseers of the Tufts University School of Medicine; Chairman and Founder of US based Atlantic Medical Management LLP.

 

Michael Bradfield
Non-Executive Director | Appointed: Apr. 2013 | Nationality: British


Skills and experience


Over 30 years experience of direct marketing and the insurance industry; law degree from LSE.

Current Appointments


Active investment manager, especially in technology based companies and sustainable industries.

Previous Appointments


Founder and CEO of Hospital Plan Insurance Services ("HPIS"), a direct seller of low cost health, accident and life insurance (subsequently sold to AIG in 2000); computer application programmer.

 

Hans von Celsing
Non-Executive Director | Appointed: January 2017 | Nationality: Swedish


Skills and experience


Over 30 years of experience from the Life Science Industry, primarily in the medical technology sector. Hans held senior positions in radiation oncology companies.

Current Appointments


Executive Chairman of CLS AB; Executive Chairman of Gelexir Healthcare Ltd; Chairman of Peptonic Medical; Chairman of Partner Fondkommission AB

Previous Appointments


Executive Vice President of Elekta AB; Advisor to Mevion Medical Systems Inc.; Chairman of Bioxydyn Ltd; Chairman of Mirada Medical.

 

Prof Steve Myers
ADAM Executive Chairman | Appointed: Nov. 2015 | Nationality: British


Skills and experience


Electronic engineer who works in high-energy physics; completed a Ph.D at Queen's University, Belfast in 1972 before joining CERN; appointed CERN Director of Accelerators and Technology and Head of CERN Medical Applications; honorary member of the European Physical Society and of the Royal Irish Academy; won the Duddell Medal and Prize of the Institute of Physics and the International Particle Accelerators Lifetime Achievement Prize "for his numerous outstanding contributions to the design, construction, commissionimg, performance optimization, and upgrade of energy-frontier colliders - in particular ISR, LEP, and LHC - and to the wider development of accelerator science”; jointly awarded the EPS Edison Volta Prize and the Prince of Asturias Prize of Spain; became an Officer of the Order of the British Empire.

Role / Responsibilities


Steve is responsible for monitoring, supervising and driving the overall technical and engineering aspects of ADAM activities, scrutinising the technical projections and targets of ADAM regularly assess performance against those targets; and reviewing technical and engineering designs with particular regard to the overall design of the accelerator.

 

Dr Nick Plowman
Chairman, medical advisory board | Appointed: | Nationality:


Skills and experience


Dr Nick Plowman is head of Clinical Oncology at St Bartholomew’s Hospital and Senior Clinical Oncologist to the Hospital for Sick Children at Great Ormond Street ("GOSH") in London. He has more than thirty years’ experience in radiation oncology in adults and children – pioneering lens sparing ocular radiotherapy, linac based radiosurgery and later being heavily involved in Gamma Knife, IMRT, and Cyberknife projects. Dr. Plowman is the director of The CyberKnife Centre London on Harley Street.

Dr Plowman probably has the UK’s widest experience in new radiation techniques and paediatric radiotherapy and has written widely on critical appraisals of new and existing techniques. He has published some twenty original research papers on intracranial radiosurgery and the UK’s first research paper on spinal radiosurgery. Dr Plowman part funds a laboratory project at Brunel University exploring DNA repair mechanisms, their deficiencies with regards to intrinsic radiosensitivity of normal host tissues and interference with these repair mechanisms with particular regard to irradiated tumours.

 

Nicolas Serandour
Chief Executive Officer | Appointed: Sep. 2014 | Nationality: French


Skills and experience


Over 15 years of experience in the investment banking industry; extensive experience providing strategic and financial advice to senior executives at leading healthcare companies internationally.

Current Appointments


Chief Executive Officer

Previous Appointments


Previous experience at JPMorgan, Lehman Brothers and Lazard.

Headquarters

Advanced Oncotherapy plc
Third Floor
4 Tenterden Street
London
W1S 1TE
Phone: (+44) 0203 617 8728

ADAM

Advanced Oncotherapy R&D facility
11, Rue de Veyrot
1217 Meyrin
Switzerland

US Office

Advanced Oncotherapy Americas Inc
120 Walton St
Suite 301
Syracuse, USA
NY 13202

Nederland Office

Advanced Oncotherapy plc
Poortgebouw
Rijnsburgerweg 10
2333AA Leiden
Nederland

 

Headquarters

Advanced Oncotherapy plc
Third Floor
4 Tenterden Street
London
W1S 1TE
Phone: (+44) 0203 617 8728

ADAM

Advanced Oncotherapy R&D facility
11, Rue de Veyrot
1217 Meyrin
Switzerland

US Office

Advanced Oncotherapy Americas Inc
120 Walton St
Suite 301
Syracuse, USA
NY 13202

Nederland Office

Advanced Oncotherapy plc
Poortgebouw
Rijnsburgerweg 10
2333AA Leiden
Nederland

Columns Including AVO

VIEW ALL

Market Reports Including AVO

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use